Back to top

Research Daily

Tuesday, October 11, 2016

Today's Research Daily features research reports on 8 major stocks, including Chevron Corp. (CVX), Cisco Systems, Inc. (CSCO) and GlaxoSmithKline plc (GSK).

Chevron shares have responded more positively to the recent oil-price momentum than some of its other super-major peers given the company's oilier asset base. The stock is modestly down in the morning session today, but is up more than 15% year-to-date, which compares to the more defensively oriented Exxon's 13.5% gain in that same time period. Chevron's current oil and gas development project pipeline is among the best in the industry, boasting large, multi-year projects. The company has remained competitive by embarking on aggressive cost reduction initiatives, exiting unprofitable markets and streamlining the organization. (You can read the full research report on Chevron here>>)

Cisco shares have outperformed the broader market as well as the Tech sector this year (the stock is up 15.9% year-to-date), likely reflecting the market's greater appreciation for the networking giant's strong market position, product range, growth initiatives, new investments and attractive dividend. Additionally, overall growth prospects remain positive because of the drive toward cloud computing and increasing data flow on carrier and computing networks. Recently, Cisco and salesforce.com announced a partnership to integrate their cloud platforms. However, the increasing competition and challenges in China remain concerns. (You can read the full research report on Cisco here>>)

GlaxoSmithKline shares have outperformed its large-cap pharma peers given the company's positioning to deliver strong core earnings growth on the back of performance momentum in its new products as well as those acquired from Novartis. These should help support revenues and ease the impact of the loss of Advair sales. Glaxo’s efforts to develop its pipeline are also encouraging. Moreover, steps to increase cost efficiency and its outlook for the next five years bode well. (You can read the full research report on GlaxoSmithKline here>>)

Other noteworthy reports we are featuring today include NIKE, Inc. (NKE), The Boeing Company (BA) and BP p.l.c. (BP).

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand.  Click for his prized selections right now >> 

You can find all of today's stock research reports here>>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

No New Upgrades.

New Downgrades

No New Downgrades.